0.89%| Prev Close: | 73.69 |
|---|---|
| Open: | 74.68 |
| Bid: | 68.11 x 100 |
| Ask: | 76.10 x 100 |
| 1y Target Est: | 52.38 |
| Beta: | 1.03 |
| Next Earnings Date: | N/A |
| Day's Range: | 71.99 - 74.88 |
|---|---|
| 52wk Range: | 42.47 - 76.57 |
| Volume: | 1,828,710 |
| Avg Vol (3m): | 1,357,620 |
| Market Cap: | 22.06B |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.38 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Why Hyperion Therapeutics Shares Shot Higherat Motley Fool(Thu 4:24PM EDT)
- Valeant Pharmaceuticals International Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu 11:50AM EDT)
- Valeant Pharma takes 1Q loss on Medicis costsAP(Thu 11:49AM EDT)
- Alternative Dosage Forms Create Barriers Against Competition in Generics: A Wall Street Transcript Interview with David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co.Wall Street Transcript(Thu 11:08AM EDT)
- Valeant, Actavis Q1 Earnings Beat Views, Sales Missat Investor's Business Daily(Thu 11:02AM EDT)
- UPDATE 2-Valeant raises profit forecast, hunts for dealsat Reuters(Thu 9:21AM EDT)
- Hyperion Therapeutics Exercises Option to Acquire Rights to BUPHENYL(R) and AMMONUL(R)GlobeNewswire(Thu 9:00AM EDT)
- Valeant Pharmaceuticals International Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Thu 8:58AM EDT)
- UPDATE 1-Valeant adjusted profit up; raises profit forecastat Reuters(Thu 7:36AM EDT)
- InPlay: Valeant Pharma beats by $0.05, misses on revs; raises FY13 EPS guidance, reaffirms revsBriefing.com(Thu 6:36AM EDT)
- Valeant posts bigger loss as costs riseat Reuters(Thu 6:19AM EDT)
- Valeant Pharmaceuticals Reports 2013 First Quarter Financial ResultsCNW Group(Thu 6:06AM EDT)
- Valeant Pharmaceuticals Reports 2013 First Quarter Financial ResultsPR Newswire(Thu 6:00AM EDT)
- VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, FinancEDGAR Online(Wed, May 1)
- Valeant Pharmaceuticals International Inc (VRX): Today's Featured Drugs Laggardat TheStreet(Wed, May 1)
Press Releases
- Hyperion Therapeutics Exercises Option to Acquire Rights to BUPHENYL(R) and AMMONUL(R)GlobeNewswire(Thu 9:00AM EDT)
- Valeant Pharmaceuticals Reports 2013 First Quarter Financial ResultsCNW Group(Thu 6:06AM EDT)
- Valeant Pharmaceuticals Reports 2013 First Quarter Financial ResultsPR Newswire(Thu 6:00AM EDT)
Reports
- Thomson Reuters Stock Report - VALEANT PHARMACEUTICALS INTERNATIONAL INC (VRX-N)Thomson Reuters Stock Report(May 2)
- VRX: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 2)
- Trading Report for (VRX). A detailed report, including free correlated market...Stock Traders Daily(May 2)